To predict arrhythmic risk in carriers of filamin C truncating variants, a novel risk predictive model was developed based on ...

Johnson & Johnson said on Friday it resumed the limited market release of its Varipulse heart device in the United States ...

Johnson & Johnson MedTech announced that it intends to resume the rollout of its Varipulse platform in the U.S. after a ...

The instructions for use have been updated to address issues that led to a greater risk of neurovascular events in an early ...

Johnson & Johnson is set to resume the limited market release of the Varipulse Catheter, a treatment option for atrial ...

J&J said it found no immediate procedure-related causes from the atrial fibrillation therapy but that risks can escalate if a ...

J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S.

Johnson & Johnson (JNJ) stock in focus as limited rollout of Varipulse heart device resumes after a safety review prompted by ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Johnson & Johnson said the U.S. rollout of the Varipulse pulsed field ablation platform is back on after an ...

A recent pause in U.S. sales of Varipulse is hampering the company’s bid to catch up in one of the industry’s fastest-growing ...